Sunday, August 23, 2026
21 C
Bengaluru

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Summary of Performance of Top 30 Metros in IPM – Dec’24

Overall Market Performance
• The top 30 metros in India contributed 34% to the total IPM (Indian Pharmaceutical Market) sales for MAT (Moving Annual Total) Dec’24.
• These cities grew at a rate of 8.5%, slightly higher than the overall IPM growth of 7.6%.
• The total market value of these 30 metros increased from ₹71,831 Cr (Dec’23) to ₹77,929 Cr (Dec’24), showing a ₹6,098 Cr increase.

Fastest-Growing Markets
• Top 5 fastest-growing metros:
1. Pune (15%)
2. Agra (14%)
3. Lucknow (13%)
4. Nashik (13%)
5. Delhi (12.5%)
Among the six mega metros, Delhi grew the fastest at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).

Growth Trends & Insights
• 13 out of 30 metros grew faster than the IPM growth rate (7.6%), while 17 metros grew at or below the IPM growth rate.
• Cities like Delhi, Hyderabad, Bangalore, and Chennai remain dominant in total market value, with Delhi leading at ₹10,756 Cr.
• Smaller cities like Bhopal (12%) and Nashik (13%) showed strong growth, indicating increasing pharmaceutical demand in Tier-2 cities.

Conclusion

The Indian pharmaceutical market continues to grow robustly, especially in urban centers. While mega metros remain strong contributors, smaller cities like Lucknow, Pune, and Agra are emerging as high-growth markets. The steady expansion of IPM in these metros suggests increasing healthcare accessibility and demand for pharmaceutical products in urban India.

Hot this week

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Topics

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...
spot_img

Related Articles

spot_imgspot_img